Drug intelligence / Profile preview

KOVIR

Development stage: Phase 3
Lead developer: Sao Thai Duong
Administration: Oral

Overview

KOVIR is a dietary supplement developed by Sao Thai Duong Joint Stock Company, rooted in traditional medicine principles for treating cold conditions and what is referred to as the "initial plague." It is currently being investigated for its potential role in managing COVID-19 in patients without acute respiratory failure. KOVIR is available in different formulations, including a softgel (TD.0068) containing Allium sativum extract, Colostrum, and mixed herbs, and a hard capsule (TD0069) primarily composed of fine powder mixed medicinal herbs.

Brand names: Sunkovir
Other names: Kovir

Beyond the preview

Go deeper on KOVIR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KOVIR.

Explore the full profile